T. Rowe Price Associates’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$17.2M Sell
624,159
-18,789
-3% -$518K ﹤0.01% 989
2025
Q1
$18.2M Sell
642,948
-430,107
-40% -$12.2M ﹤0.01% 981
2024
Q4
$44.6M Sell
1,073,055
-386,924
-27% -$16.1M 0.01% 788
2024
Q3
$97.6M Sell
1,459,979
-139,749
-9% -$9.34M 0.01% 568
2024
Q2
$190M Buy
1,599,728
+580,531
+57% +$68.9M 0.02% 426
2024
Q1
$109M Sell
1,019,197
-88,298
-8% -$9.41M 0.01% 530
2023
Q4
$110M Sell
1,107,495
-387,543
-26% -$38.5M 0.01% 523
2023
Q3
$154M Buy
1,495,038
+293,604
+24% +$30.3M 0.02% 437
2023
Q2
$146M Sell
1,201,434
-411,017
-25% -$49.9M 0.02% 448
2023
Q1
$248M Sell
1,612,451
-1,116,552
-41% -$171M 0.04% 344
2022
Q4
$490M Sell
2,729,003
-3,714,406
-58% -$667M 0.08% 233
2022
Q3
$762M Buy
6,443,409
+3,051,035
+90% +$361M 0.12% 163
2022
Q2
$485M Buy
3,392,374
+973,933
+40% +$139M 0.06% 296
2022
Q1
$417M Sell
2,418,441
-13,367
-0.5% -$2.3M 0.04% 363
2021
Q4
$618M Sell
2,431,808
-6,282
-0.3% -$1.6M 0.06% 313
2021
Q3
$938M Buy
2,438,090
+215,515
+10% +$82.9M 0.09% 233
2021
Q2
$522M Sell
2,222,575
-115,320
-5% -$27.1M 0.05% 326
2021
Q1
$306M Buy
2,337,895
+993,175
+74% +$130M 0.03% 438
2020
Q4
$140M Buy
1,344,720
+356,183
+36% +$37.2M 0.01% 613
2020
Q3
$69.9M Sell
988,537
-28,323
-3% -$2M 0.01% 762
2020
Q2
$65.3M Buy
1,016,860
+491,217
+93% +$31.5M 0.01% 761
2020
Q1
$15.7M Sell
525,643
-603,854
-53% -$18.1M ﹤0.01% 1139
2019
Q4
$22.1M Buy
1,129,497
+334,486
+42% +$6.54M ﹤0.01% 1149
2019
Q3
$12.7M Sell
795,011
-40,416
-5% -$643K ﹤0.01% 1251
2019
Q2
$12.2M Buy
835,427
+15,652
+2% +$229K ﹤0.01% 1280
2019
Q1
$16M Buy
819,775
+6,333
+0.8% +$123K ﹤0.01% 1238
2018
Q4
$11.9M Buy
+813,442
New +$11.9M ﹤0.01% 1283